LIN28B encodes an RNA-binding protein that functions as a central regulator of developmental timing in mammals. By suppressing let-7 microRNAs¹¹ let-7 microRNAs
A class of small non-coding RNAs that promote cellular differentiation and suppress growth signals; rising let-7 levels mark the transition from a growth-permissive to a maturation state, LIN28B activity holds the hypothalamic-pituitary-gonadal (HPG) axis in a pre-pubertal state. When LIN28B expression falls below a developmental threshold, let-7 levels rise and the GnRH pulse generator activates, initiating puberty. Common regulatory variants near LIN28B shift this threshold, making the pubertal transition arrive slightly earlier or later at the population level.

rs314276 is an intronic variant at chromosome 6q16.3 — the same LIN28B locus as rs7759938 (also studied in this platform), but in low linkage disequilibrium with it. Multiple studies examining both variants simultaneously have confirmed that they are partially independent signals within the LIN28B region, likely tagging distinct regulatory haplotypes that each modulate LIN28B expression to different degrees.

The Mechanism

rs314276 lies within an intron of LIN28B at GRCh38 position Chr6:104,960,124. The A and C alleles are on the plus strand; the C allele is the more common allele globally (~65% frequency) and is associated with somewhat earlier puberty timing. The variant most likely acts as a tag for a regulatory element that influences LIN28B expression in hypothalamic or pituitary tissue — the precise causal variant has not been isolated at this locus. As with rs7759938, the functional consequence is quantitative and probabilistic, shifting the population distribution of puberty onset rather than deterministically controlling it. Each C allele may shift the average age at menarche approximately 1–2 months earlier.

The Evidence

Ong et al. (2009)²² Ong et al. (2009)
Nature Genetics; 4,714 discovery + 16,373 replication women was the primary discovery paper for rs314276. In the GWA stage, each C allele was associated with 0.22 years (95% CI: 0.14–0.29) earlier menarche; in the larger replication stage the estimate converged to 0.12 years (95% CI: 0.08–0.16; p=3.6×10⁻¹⁶ combined), consistent with the winner's curse phenomenon. Effects on male pubertal milestones were also demonstrated: earlier voice breaking (p=0.006; n=1,026) and more advanced pubic hair development (p=0.01; n=4,588). Girls with earlier LIN28B-driven puberty also showed higher BMI during the mid-childhood and adolescent growth period.

In a longitudinal UK cohort of 2,451 individuals followed from ages 2–53 years, Ong et al. (2011)³³ Ong et al. (2011)
JCEM; MRC National Survey of Health and Development found the C allele at rs314276 was associated with higher BMI specifically in women from ages 15–43, with the effect peaking around age 26 and then declining. No association was found with adult obesity or with BMI in men, consistent with a transient, puberty-mediated adiposity shift rather than a long-term metabolic risk.

In Taiwanese girls, Chen YC et al. (2017)⁴⁴ Chen YC et al. (2017)
JPEM; 116 CPP cases, 102 controls found CC homozygotes at rs314276 were significantly more common in central precocious puberty cases. This aligns with the mechanism: higher C allele dosage may associate with greater LIN28B regulatory activity at this tag SNP, advancing the HPG axis earlier into the precocious puberty range for some individuals.

A smaller study of 248 Greek girls Tsinopoulou et al. (2024)⁵⁵ Tsinopoulou et al. (2024)
Children; n=248 found no significant association in that cohort, likely reflecting inadequate power to detect the modest per-allele effect (~1–2 months) in a small population. This does not contradict the larger replicated studies.

Practical Implications

The per-allele effect of rs314276 on menarche (~1–2 months per C allele) is modest at the individual level, but the biological framing matters: two C alleles places a person in the earlier-maturing portion of the LIN28B locus haplotype space. When combined with rs7759938 status, the combined picture of LIN28B regulatory variation may be more informative than either SNP alone. Earlier menarche carries implications for total lifetime estrogen exposure, uterine fibroid risk, and reproductive planning context — as documented in the broader LIN28B literature.

For females, the key action-relevant insight for CC carriers is that cumulative estrogen exposure begins somewhat earlier, which is associated (at the population level) with moderately elevated uterine fibroid risk over the lifespan. For males, the variant may contribute to earlier pubertal milestones but has no specific actionable consequence in isolation.

The BMI finding from Ong et al. is worth noting for clinical context: CC carriers may tend toward higher BMI during adolescence and young adulthood due to the earlier and faster growth tempo, not due to metabolic dysfunction. This typically normalizes in adulthood.

Interactions

rs7759938 (LIN28B): rs314276 and rs7759938 are at the same LIN28B locus but are in low linkage disequilibrium with each other. Multiple population studies (Russian and Greek cohorts examining both variants simultaneously) describe the overall LIN28B LD structure as showing low pairwise r² across the four main tag SNPs in this region. rs7759938 was the lead SNP in the Perry et al. (2009) GWAS; rs314276 was the lead in the concurrent Ong et al. (2009) GWAS. They tag partially distinct haplotype effects. Individuals who are CC at rs314276 and TT at rs7759938 may carry the strongest combination of LIN28B puberty-advancing haplotypes at this locus — a compound action is proposed for the supervisor.

rs314280 (LIN28B): A third LIN28B tag SNP also studied in the menarche literature. Together with rs314276 and rs7759938, these three variants define the main haplotype diversity at the LIN28B locus for puberty-timing research.

PCOS-related variants: As demonstrated in the Carroll et al. (2012) PCOS data for rs7759938, LIN28B puberty-advancing alleles show amplified effects on menarche timing in hyperandrogenic contexts. This may also apply to rs314276 CC homozygotes with concurrent PCOS-pathway variants, though direct data are not available for rs314276 specifically in PCOS populations.

The IL12B gene¹¹ IL12B gene
located at 5q33.3, encodes the 40 kDa p40 subunit shared by two functionally distinct cytokines: IL-12 (p40/p35 heterodimer, drives Th1 and IFN-γ production) and IL-23 (p40/p19 heterodimer, drives Th17 expansion and IL-17 production). Both arms of this axis converge on psoriatic inflammation — IL-12/Th1 activates keratinocytes via IFN-γ while IL-23/Th17 drives epidermal hyperproliferation through IL-17. rs3212227 is a 3'-UTR variant at chr5:159315942 (GRCh38) in the IL12B gene. Because IL12B is transcribed from the minus strand, papers describe this variant using coding-strand notation as "1188A>C" — the A allele in coding-strand notation corresponds to the T allele on the plus (reference) genomic strand, which is what genome files report. The T allele (risk) is the major allele globally (~72%) and in Europeans (~80%). rs3212227 is the most widely studied SNP at the IL12B locus for psoriasis susceptibility and is the primary anchor of the canonical two-SNP risk haplotype with [rs6887695 | an upstream IL12B variant approximately 60 kb from the coding region that forms the best-characterised IL12B psoriasis haplotype together with rs3212227]. p40 is also the direct molecular target of [ustekinumab (Stelara) | a monoclonal antibody blocking both IL-12 and IL-23 simultaneously by binding their shared p40 subunit], making rs3212227 both a susceptibility marker and a pharmacogenomic predictor of biologic treatment outcome.

The Mechanism

The 3'-UTR location of rs3212227 places it in a regulatory sequence that influences IL12B mRNA stability and translational efficiency. The risk haplotype defined by rs6887695G/rs3212227T (plus-strand notation) substantially amplifies IL12B transcription. Johnston et al. 2013²² Johnston et al. 2013
Susceptibility-associated genetic variation at IL12B enhances Th1 polarization in psoriasis, Journal of Investigative Dermatology demonstrated that homozygous risk carriers show on average 12.5-fold higher IL12B expression after monocyte stimulation compared to homozygous non-carriers, with approximately 6-fold elevated serum IL-12 and markedly elevated IFN-γ and the IFN-γ-induced chemokine CXCL10. Paradoxically, IL-23 levels decreased ~1.4-fold in risk carriers — this skew toward Th1 over Th17 reflects an autoregulatory feedback where excess IL-12 promotes Th1 differentiation at the expense of the Th17 arm. The net clinical effect is chronic skin inflammation driven predominantly by the IFN-γ/Th1 axis in high-IL12B-expression individuals, while lower expressors show more balanced Th1/Th17 disease. The protective G allele (plus-strand) corresponds to coding-strand C, and tags a regulatory state that restrains this IL12B amplification.

The Evidence

rs3212227 was established as the primary IL12B psoriasis susceptibility SNP by Cargill et al. 2007³³ Cargill et al. 2007
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes, a landmark study of 1,446 cases and 1,432 controls across three independent white North American cohorts reporting OR 0.64 for the protective allele (Pcomb = 7.85×10⁻¹⁰). This study also described the canonical two-SNP risk haplotype with rs6887695 (OR 1.40 for the risk haplotype). The findings were replicated and extended by Nair et al. 2008⁴⁴ Nair et al. 2008
Polymorphisms of the IL12B and IL23R genes are associated with psoriasis in 1,810 cases and 2,522 controls plus 509 family pedigrees, yielding OR 1.62 for rs3212227 (P = 1.7×10⁻¹⁵) — among the highest effect sizes reported for any psoriasis susceptibility SNP outside the MHC. A meta-analysis of 11 studies (Zhu et al. 2013)⁵⁵ meta-analysis of 11 studies (Zhu et al. 2013)
Meta-analysis of IL12B polymorphisms (rs3212227, rs6887695) with psoriasis and psoriatic arthritis confirmed OR 0.688 (95% CI 0.650–0.729) for the protective minor allele in psoriasis and OR 0.707 (95% CI 0.628–0.797) in psoriatic arthritis, with consistent signal across ethnicities.

For pharmacogenomics, Galluzzo et al. 2016⁶⁶ Galluzzo et al. 2016
IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction found that in HLA-Cw6 positive psoriasis patients treated with ustekinumab, the absence of the homozygous risk genotype at rs3212227 significantly increased the probability of therapeutic success. This identifies rs3212227 as a pharmacogenomic stratifier for anti-p40 biologic therapy: individuals carrying at least one protective G allele (TG or GG) show better early treatment responses to ustekinumab than TT homozygotes.

The IL12B susceptibility locus is also shared with inflammatory bowel disease. The IL-12/IL-23 pathway drives mucosal inflammation in Crohn's disease and ulcerative colitis, and IL12B variants have been consistently associated with IBD susceptibility. The same p40-targeting mechanism underlies ustekinumab's FDA approval for both moderate-to-severe plaque psoriasis and Crohn's disease.

Practical Actions

For TT homozygotes (the majority of people), the clinical relevance is twofold. For psoriasis susceptibility: TT individuals have the highest genetic load at the IL12B locus and lack the protective regulatory effect of the G allele. For pharmacogenomics: when ustekinumab is being considered for psoriasis or Crohn's disease, TT homozygotes are in the group with the least favourable early response profile — this does not rule out the drug, but argues for setting realistic expectations about early PASI response timelines and for closely monitoring treatment progress at 3 months. TG heterozygotes and GG homozygotes have incrementally better response profiles.

For carriers of the protective G allele (TG or GG), this result is actively useful: if psoriasis develops and biologic therapy is indicated, the genotype supports ustekinumab as a rational first-line choice, particularly when combined with HLA-Cw6 typing. Guselkumab and risankizumab target only the IL-23-specific p19 subunit rather than the shared p40; their response prediction is not directly influenced by rs3212227 in the same way.

The IBD connection is clinically relevant across all genotypes: TT homozygotes carrying the highest IL12B-driven inflammation risk should be aware of the psoriasis-IBD comorbidity and investigate persistent gastrointestinal symptoms.

Interactions

rs3212227 and rs6887695 together define the canonical IL12B psoriasis risk haplotype; they are the most extensively studied pair at this locus and should be considered jointly for haplotype-level risk assessment. Both are now in the GeneOps database. rs3213094 (IL12B intronic) is in partial linkage disequilibrium with rs3212227 and has independent pharmacogenomic value for ustekinumab response prediction (Galluzzo 2016); carrying risk alleles at both rs3212227 and rs3213094 marks the highest IL12B-driven psoriasis susceptibility subgroup. rs11209026 (IL23R R381Q) is a strongly protective IL-23 receptor loss-of-function variant; carriers of both the IL12B TT risk genotype and the IL23R protective A allele have a partially antagonistic combination where elevated p40 production is partially offset by reduced receptor sensitivity downstream. rs12188300 (near-gene IL12B regulatory) was identified in the same German psoriasis GWAS screen and represents an independent signal at the 5q33.3 locus.

The NLRP3 gene encodes the central sensing component of the NLRP3 inflammasome¹¹ NLRP3 inflammasome
A multiprotein innate immune complex that acts as an intracellular danger sensor, assembling in response to pathogens, crystals, fatty acids, and other signals — the innate immune platform responsible for producing IL-1beta and IL-18²² IL-1beta and IL-18
Two cytokines that drive fever, neutrophil recruitment, and systemic inflammatory cascades, two of the most potent pro-inflammatory cytokines in the body. Q705K (rs35829419) is a common missense variant that substitutes glutamine for lysine at position 703 of the protein (also referred to in older literature as position 705 due to differing isoform numbering). Unlike rare NLRP3 mutations that cause the severe cryopyrin-associated periodic syndromes (CAPS)³³ cryopyrin-associated periodic syndromes (CAPS)
Rare autoinflammatory disorders including Muckle-Wells syndrome and familial cold autoinflammatory syndrome, Q705K is a common polymorphism in European populations (about 4% carry the A allele) that subtly but measurably lowers the threshold for inflammasome activation.

The Mechanism

The Q705K substitution introduces a charged lysine residue into the NLRP3 protein's central domain, altering the conformational dynamics of the complex. Functional studies using THP-1 monocytic cells transduced with Q705K showed a five-fold increase in IL-1beta production at baseline compared to wild-type cells, without any external stimulation⁴⁴ Functional studies using THP-1 monocytic cells transduced with Q705K showed a five-fold increase in IL-1beta production at baseline compared to wild-type cells, without any external stimulation
This spontaneous activation distinguishes Q705K from normal NLRP3 behavior. Upon exposure to alum (a vaccine adjuvant and NLRP3 activator), Q705K cells produced an additional two-fold more IL-1beta than wild-type cells. The excess cytokine production operates through an autocrine feedback loop⁵⁵ autocrine feedback loop
Secreted IL-1beta binds IL-1 receptors on the same cell, amplifying downstream signaling and further driving inflammasome activation via the IL-1 receptor. Blocking either caspase-1 (the inflammasome effector enzyme) or the IL-1 receptor substantially reduces the excess production, confirming the inflammasome as the source.

The NLRP3 inflammasome is activated by a diverse array of danger signals: monosodium urate (MSU) crystals⁶⁶ monosodium urate (MSU) crystals
The deposited form of uric acid in gout in gout, intracellular lipid crystals from high saturated fat intake, cholesterol crystals in atherosclerotic plaques⁷⁷ cholesterol crystals in atherosclerotic plaques
NLRP3 activation in macrophages within arterial walls contributes to plaque instability, and bacterial toxins in the gut. With a gain-of-function Q705K variant, all of these triggers produce an amplified response.

The Evidence

A meta-analysis of 13 case-control studies totalling 7,719 patients found that the rs35829419 A allele was significantly associated with increased susceptibility across multiple inflammatory diseases⁸⁸ significantly associated with increased susceptibility across multiple inflammatory diseases
Including leprosy, colorectal cancer, HIV-1 infection, rheumatoid arthritis, abdominal aortic aneurysms, inflammatory bowel disease, ulcerative colitis, and atopic dermatitis.

For gout, the pathway is direct: uric acid crystals are among the most potent NLRP3 activators known, and the gain-of-function Q705K variant lowers the threshold for crystal-induced IL-1beta production. NLRP3 polymorphisms have been identified as contributors to gout susceptibility across multiple populations⁹⁹ NLRP3 polymorphisms have been identified as contributors to gout susceptibility across multiple populations, and the Q705K gain-of-function variant amplifies MSU-crystal-induced IL-1beta production through the same pathway, though its individual contribution to gout risk is most clearly manifest through pathway biology rather than isolated genetic association.

For inflammatory bowel disease, a landmark Swedish cohort study demonstrated that men carrying both the NLRP3 Q705K allele and the CARD8 C10X allele (rs2043211) had OR 3.40 (95% CI 1.32-8.76, p=0.011) for Crohn's disease¹⁰¹⁰ OR 3.40 (95% CI 1.32-8.76, p=0.011) for Crohn's disease
This gene-gene interaction between NLRP3 and its negative regulator CARD8 dramatically amplifies risk when both are compromised compared to those carrying neither variant. This is a gene-gene interaction of substantial clinical magnitude.

For metabolic inflammation and cardiovascular risk, a Slovenian study of 181 type 2 diabetes patients found that A allele carriers had OR 3.93 (95% CI 1.54-10.0, p=0.004) for macrovascular complications¹¹¹¹ A allele carriers had OR 3.93 (95% CI 1.54-10.0, p=0.004) for macrovascular complications
Including peripheral arterial occlusive disease, myocardial infarction, and ischemic cerebrovascular disease, even after adjusting for diabetes duration and cholesterol. The association was strongest in men.

Notably, a meta-analysis examining rs35829419 specifically in autoimmune diseases found a protective effect against rheumatoid arthritis (OR 0.74, 95% CI 0.57-0.96)¹²¹² protective effect against rheumatoid arthritis (OR 0.74, 95% CI 0.57-0.96)
The A allele may reduce susceptibility to RA through complex immune regulatory mechanisms, illustrating that the same gain-of-function variant can have disease-context-specific effects — enhancing innate immune responses that damage joints in gout while potentially reducing adaptive autoimmune processes in RA.

Practical Actions

The NLRP3 inflammasome is a well-validated druggable target. The most relevant dietary interventions work through two complementary mechanisms: increasing endogenous inhibitors of NLRP3 activation, and reducing the triggers that activate it.

EPA and DHA (omega-3 fatty acids) directly suppress NLRP3 inflammasome assembly¹³¹³ EPA and DHA (omega-3 fatty acids) directly suppress NLRP3 inflammasome assembly
Acting via GPR120 and GPR40 receptors and their downstream scaffold protein beta-arrestin-2, abolishing caspase-1 activation and IL-1beta secretion in macrophages. In animal models, omega-3 supplementation prevented NLRP3-driven metabolic inflammation in high-fat diet models. For Q705K carriers, a consistent, clinically meaningful EPA/DHA intake represents the most evidence-backed dietary strategy.

Sulforaphane, the isothiocyanate produced from glucoraphanin in broccoli sprouts¹⁴¹⁴ Sulforaphane, the isothiocyanate produced from glucoraphanin in broccoli sprouts
Broccoli sprouts contain 10-100x more glucoraphanin than mature broccoli, inhibits NLRP3 inflammasome activation by reducing reactive oxygen species and suppressing IL-1beta and IL-18 secretion.

Avoidance matters equally: dietary triggers that activate NLRP3 include fructose and alcohol (which raise serum uric acid, a potent NLRP3 activator and the pathogenic agent in gout) and high saturated fat intake, particularly palmitate¹⁵¹⁵ high saturated fat intake, particularly palmitate
Palmitate activates NLRP3 in macrophages through mitochondrial reactive oxygen species and the AMPK-autophagy signaling cascade.

Interactions

The most clinically significant interaction is with rs2043211 (CARD8 C10X). CARD8 is an endogenous negative regulator of NLRP3 — it normally dampens inflammasome activity. The C10X loss-of-function variant eliminates CARD8 function. When NLRP3 is gain-of-function (Q705K) AND its brake is absent (CARD8 C10X), the combinatorial effect in men is a 3.40-fold increase in Crohn's disease risk — far larger than either variant alone. This is a compound interaction that warrants a dedicated compound action for users carrying both genotypes.

rs2066844 (NOD2 R702W) and other NOD2 loss-of-function variants reduce bacterial sensing in the gut, placing additional pressure on NLRP3-driven innate immunity as a compensatory pathway. Carriers of both NLRP3 Q705K and a NOD2 risk variant may have dysregulated intestinal innate immunity from two directions. The compound recommendation would be heightened vigilance for IBD symptoms and close dietary management of NLRP3 triggers.

The rs10754558 NLRP3 3'UTR variant affects NLRP3 expression level via microRNA regulation and may act additively with Q705K — higher expression of an already gain-of-function protein further amplifies IL-1beta output.

Protein C is the body's front-line anticoagulant brake. Released into circulation as an inactive precursor, it is activated when thrombin binds thrombomodulin¹¹ thrombomodulin
a receptor on endothelial cells lining blood vessels that converts thrombin from a procoagulant to an anticoagulant enzyme on the vessel wall. Activated protein C (APC) then cleaves and inactivates coagulation factors Va and VIIIa²² factors Va and VIIIa
both are essential amplifiers of the coagulation cascade; Va is a cofactor for prothrombinase, and VIIIa is a cofactor for the tenase complex — inactivating them shuts down clot propagation, dramatically slowing clot propagation. Without adequate protein C, coagulation continues unchecked after the initial trigger, raising the probability of pathological thrombosis.

The rs369504169 A allele introduces a c.125G>A substitution³³ c.125G>A substitution
nucleotide 125 of the coding sequence; G is the GRCh38 plus-strand reference base at chr2:127,421,337 in exon 3 of PROC, replacing the arginine at position 42 with histidine (p.Arg42His). ClinVar classifies this variant as likely pathogenic, with submissions documenting affected individuals with autosomal dominant thrombophilia and documented deep venous thrombosis. The variant is extremely rare globally — the A allele is present at approximately 0.001% frequency or less across all gnomAD populations.

The Mechanism

Arginine 42 lies within the Gla domain⁴⁴ Gla domain
a vitamin K-dependent gamma-carboxyglutamic acid (Gla) domain at the N-terminus of protein C; this domain binds calcium and anchors the protein to phospholipid membranes on endothelial surfaces, positioning it to interact with thrombomodulin and to be activated by the thrombin-thrombomodulin complex of the protein C precursor. Substituting positively charged arginine with histidine alters the local charge environment of this domain, which is thought to impair proper membrane anchoring or receptor interaction. Studies of closely related arginine residues in the Gla domain have confirmed that charge changes at these positions reduce protein C functional activity — the p.Arg42His variant has been noted to produce discrepant results between amidolytic (chromogenic substrate) assays and clotting-based functional assays, which is a hallmark of Type II protein C deficiency⁵⁵ Type II protein C deficiency
normal antigen level but reduced functional activity; contrasts with Type I where both antigen and activity are reduced proportionally.

Heterozygous carriers produce one functional and one impaired protein C allele, resulting in approximately 50-65% of normal protein C activity — below the 70 IU/dL threshold typically considered normal. This partial deficiency is sufficient to elevate venous clotting risk without causing the catastrophic thrombosis seen in homozygotes (who typically have protein C activity below 1%).

The Evidence

A meta-analysis of 107,130 individuals across 107 publications⁶⁶ meta-analysis of 107,130 individuals across 107 publications
Alnor et al., Annals of Hematology, 2024; 21,560 VTE events analysed found that protein C deficiency carries an odds ratio of 3.23 (95% CI 2.05-5.08) for a first venous thromboembolism. Earlier prospective data from a cohort study tracking relatives of protein S, protein C, and antithrombin deficiency probands found an annual VTE incidence of 1.53%⁷⁷ annual VTE incidence of 1.53%
compared to 0.29% in unaffected relatives; adjusted hazard ratio 7.0 (95% CI 2.7-18.0) in affected individuals — a 7-fold increase.

The specific p.Arg42His (c.125G>A) variant was identified as novel in a 2025 case report of neonatal purpura fulminans⁸⁸ 2025 case report of neonatal purpura fulminans
Francis et al., Indian Journal of Dermatology, 2025, where a homozygous infant presented with disseminated intravascular coagulation and vitreous haemorrhage — consistent with the near-complete absence of protein C in biallelic carriers. In heterozygous form, p.Arg42His has been documented in patients with deep venous thrombosis and thromboembolism⁹⁹ patients with deep venous thrombosis and thromboembolism
NIHR ThromboGenomics study, n=2,396 patients sequenced; rs369504169 identified as likely pathogenic by ACMG criteria by the NIHR ThromboGenomics consortium.

The 2023 American Society of Hematology guidelines on thrombophilia testing¹⁰¹⁰ 2023 American Society of Hematology guidelines on thrombophilia testing
Middeldorp et al., Blood Advances 2023; PMID 37195076; the most current evidence-based guidance conditionally recommend testing for protein C deficiency in individuals with a family history of the deficiency when considering thromboprophylaxis for minor provoking risk factors, and specifically to guide avoidance of combined hormonal contraceptives in women.

Practical Actions

Heterozygous carriers are not inevitably destined to develop thrombosis — many live without a clot event — but the elevated baseline risk becomes clinically significant whenever additional thrombophilic triggers are present. The key risks to proactively manage are: combined hormonal contraceptives (estrogen increases coagulation factor synthesis, compounding protein C deficiency risk), high-risk surgical and immobilisation periods, and pregnancy or postpartum (already the highest-risk VTE window in women's lives).

ASH 2023 guidelines support indefinite anticoagulation after a first VTE event in confirmed protein C deficiency carriers, in contrast to the standard 3-6 months recommended for provoked VTE without thrombophilia. This makes knowing carrier status genuinely decision-changing for anticoagulation duration after any thrombotic event.

Interactions

The most clinically significant interaction involves Factor V Leiden (rs6025, F5 R506Q)¹¹¹¹ Factor V Leiden (rs6025, F5 R506Q)
Factor V Leiden prevents APC from inactivating Factor Va — when protein C is already partially deficient, this APC resistance compounds the anticoagulant failure at two independent points in the cascade. Double carriers of protein C deficiency and Factor V Leiden face substantially greater VTE risk than either variant alone. Similarly, [the prothrombin G20210A variant (rs1799963) | raises circulating prothrombin levels 30%, increasing thrombin availability and clot propagation] compounds protein C deficiency by generating more thrombin than a protein C system already running at 50-65% capacity can neutralize. These interactions warrant compound action assessment and should be documented in the medical record alongside this variant.

The kidneys filter and selectively reabsorb uric acid constantly — roughly 700 mg per day passes through the glomerular filter, and the balance between reabsorption and excretion determines your serum urate level. The SLC2A9 gene, encoding the GLUT9 transporter, is the single largest genetic determinant of this balance: it explains more of the variance in serum uric acid than any other known locus. rs4580649 is an intronic variant that marks a haplotype within the SLC2A9 gene influencing how efficiently that transporter operates at the population level.

SLC2A9 encodes GLUT9¹¹ GLUT9
Glucose Transporter 9 — despite its name, GLUT9 transports urate at rates 45–60 times faster than glucose, making it the dominant urate reabsorption channel in the kidney proximal tubule. Two isoforms mediate urate handling: the long form (GLUT9a) sits on the basolateral membrane and moves urate from the kidney interstitium back into the bloodstream, while the short form (GLUT9b) sits on the apical membrane at the tubular lumen. Together they create a net flux that determines how much urate is reabsorbed versus excreted in urine.

The Mechanism

rs4580649 (chr4:9,946,837 GRCh38) is an intronic G>A variant in SLC2A9. It does not change the GLUT9 protein sequence; its effect on urate handling is regulatory in nature — it tags a haplotype that influences transporter expression or the balance between GLUT9a and GLUT9b isoforms. The SLC2A9 locus has been shown to contain multiple independent regulatory signals across a large genomic region, and fine-mapping studies have confirmed at least five statistically separable effects on serum urate at the 4p16.1 locus (Wei et al., 2014)²² (Wei et al., 2014).

The population frequency of the A allele follows the characteristic SLC2A9 protective gradient: it is most common in populations of African ancestry (~64%), intermediate in Europeans (~43%) and Latinos (~49%), lower in South Asians (~30%), and substantially rarer in East Asians (~11%). This mirror image of gout prevalence — which is highest in East Asian and Pacific Island populations and lowest in Africans — is the same pattern seen across other well-characterized SLC2A9 protective intronic variants including rs11942223, rs6815001, and the haplotype carrying the rs12498742 proxy. The G allele (reference at GRCh38), which is the major allele in East Asian populations, is the haplotype associated with reduced renal urate clearance and elevated serum uric acid.

The Evidence

The SLC2A9 locus was simultaneously identified by two independent GWAS in 2008 as the dominant genetic regulator of serum urate. Vitart et al. found that intronic SLC2A9 variants explain 1.7–5.3% of serum uric acid variance in European populations — the largest single-locus effect known for any quantitative trait at that time (Vitart et al., 2008)³³ (Vitart et al., 2008). An independent German cohort study simultaneously reported that SLC2A9 intronic variants show markedly sex-specific effects, explaining 1.2% of urate variance in men but up to 6% in women (Döring et al., 2008)⁴⁴ (Döring et al., 2008). Per-allele effect sizes range from −0.23 to −0.36 mg/dL in men and up to −0.46 mg/dL per copy in women for the protective minor alleles at this locus.

Functional studies confirmed that GLUT9 operates as a voltage-sensitive urate uniporter. Kidney-specific deletion in mice produces a 7-fold increase in urinary urate excretion, confirming the transporter's dominant role in determining how much urate the kidney retains versus releases (Phay et al., 2018)⁵⁵ (Phay et al., 2018).

Dietary fructose interacts with SLC2A9 variants through two mechanisms: fructose metabolism in the liver generates urate via AMP catabolism, and fructose may compete with urate for renal transporter binding, amplifying the genetic effect. A Croatian island study found a significant interaction between potato (starch/glucose) consumption and SLC2A9 intronic variants on serum urate levels (Batt et al., 2010)⁶⁶ (Batt et al., 2010).

Practical Actions

For individuals carrying one or two G alleles at rs4580649, the key intervention is reducing the dietary inputs that drive urate production and excretion: eliminating fructose-sweetened beverages, limiting organ meats and shellfish, and adding low-fat dairy and adequate water intake. The effect of this specific variant compounds with other SLC2A9 risk variants (rs11942223, rs3733591) since multiple independent signals at this locus are additive. Women who are peri- or post-menopausal should monitor serum uric acid proactively, as the sex-specific amplification of SLC2A9 effects (explained by estrogen's independent promotion of renal urate excretion) means that menopause unmasks genetic risk that was previously buffered.

Interactions

rs4580649 and other SLC2A9 intronic signals: rs4580649, rs11942223, and rs6815001 are all intronic SLC2A9 variants with overlapping but non-identical population distributions. Fine-mapping of the 4p16.1 locus confirms that multiple independent effects coexist in this region (Wei et al., 2014)⁷⁷ (Wei et al., 2014). Carrying the G allele at rs4580649 alongside risk alleles at rs11942223 (T allele) and/or rs3733591 (C allele) produces additive urate elevation from each independent signal.

rs4580649 and ABCG2 rs2231142: ABCG2 mediates intestinal urate secretion, a completely separate pathway from renal reabsorption. Risk alleles at rs2231142 (Q141K) and rs4580649 together produce additive serum urate elevation that can push otherwise healthy individuals above the hyperuricemia threshold, because both the intestinal export route and the renal clearance route are simultaneously impaired.

Dietary fructose interaction: High fructose intake — particularly from sugar-sweetened beverages — compounds the effect of G-allele haplotypes at SLC2A9 by generating additional urate through hepatic AMP catabolism and possibly by competing with urate at renal transporters. Eliminating fructose-containing beverages is the highest-leverage single dietary change for G allele carriers.

The thyroid gland operates on a simple feedback loop: the pituitary releases TSH (thyroid-stimulating hormone), TSH binds receptors on thyroid follicular cells, and those cells respond by producing T4 and T3. The signal amplifier inside that thyroid cell is cyclic AMP (cAMP) — and the enzyme that silences it once it has done its job is phosphodiesterase 8B, encoded by PDE8B. A common variant near this gene, rs4704397, subtly impairs the cAMP-dampening step, leaving TSH signaling running slightly hotter and the thyroid tuned to a higher setpoint. The result is a persistent upward shift in TSH levels — small enough to be invisible on routine screening, large enough to matter for ovulation, implantation, and the earliest weeks of pregnancy.

The Mechanism

PDE8B¹¹ PDE8B
Phosphodiesterase 8B; located at chromosome 5q13.3; encodes a high-affinity, rolipram-insensitive cAMP-specific phosphodiesterase highly expressed in thyroid tissue is the dominant cAMP-clearing enzyme in thyroid follicular cells. When TSH binds its receptor, cAMP floods the cell, activating PKA and triggering thyroid hormone synthesis. PDE8B's job is to hydrolyze that cAMP signal and restore the cell to baseline — essentially the "off switch" for TSH stimulation.

The rs4704397 variant lies in intron 1 of PDE8B and is thought to reduce gene expression or alter splicing efficiency, leading to less PDE8B activity. With less cAMP clearance, the thyroid follicular cell remains mildly hyperstimulated for longer, and the pituitary senses a slightly lower free T4 output. To compensate, the pituitary releases more TSH — enough to normalize free T4 into the reference range, but resulting in a persistent TSH elevation that is genetically encoded rather than driven by autoimmune damage, iodine deficiency, or frank hypothyroidism.

This mechanism was first established in 4,300 Sardinians with replication in 4,158 additional individuals²² first established in 4,300 Sardinians with replication in 4,158 additional individuals
Arnaud-Lopez et al., Am J Hum Genet 2008; discovery p=1.3×10⁻¹¹; overall replication p=1.9×10⁻²⁰; effect of 0.13 mIU/L TSH increase per A allele. Crucially, the association disappears entirely in people taking levothyroxine replacement — confirming the effect operates upstream at the pituitary-thyroid axis, not at end-organ level.

The Evidence

The foundational genome-wide association study by Arnaud-Lopez et al. (2008)³³ Arnaud-Lopez et al. (2008)
Am J Hum Genet; n=8,458 total; discovery in 4,300 Sardinians, replication in Tuscans and Old Order Amish; rs4704397 in intron 1 of PDE8B; per-A-allele TSH increase of 0.13 mIU/L established rs4704397 as one of the strongest genetic determinants of serum TSH levels identified at that time, with effect sizes comparable to or larger than most subsequently discovered loci.

A meta-analysis of four cohorts totaling 2,557 participants⁴⁴ meta-analysis of four cohorts totaling 2,557 participants
Taylor et al., Eur J Endocrinol 2011; associations longitudinally stable across 13 years (1981 vs 1994 measurements); A allele associated with TSH increase of 0.20 standard deviations per allele (p=1.64×10⁻¹⁰) and free T4 decrease of 0.07 standard deviations (p=0.023) confirmed that the TSH-raising effect is durable over time — not a transient phenomenon — and accompanied by a reciprocal, modest reduction in free T4.

The pregnancy implications were quantified in a cohort of 970 pregnant women assessed at 28 weeks⁵⁵ 970 pregnant women assessed at 28 weeks
Shields et al., J Clin Endocrinol Metab 2009; AA genotype median TSH 2.16 vs 1.73 mIU/L in GG; at the 4.21 mIU/L upper reference limit, AA women were 2.7× more likely to exceed it (9.6% vs 3.5%, p=0.004). This means that standard population-derived reference intervals classify a substantial proportion of genetically high-TSH women as subclinically hypothyroid even when their TSH reflects a genetic setpoint rather than thyroid disease — an important nuance for clinical interpretation.

The fertility connection was established in a case-control study of infertile subclinically hypothyroid women⁶⁶ case-control study of infertile subclinically hypothyroid women
Mansuri et al., Int J Fertil Steril 2020; 60 infertile SCH cases vs 74 controls; AA genotype OR=3.84 (95% CI 1.86–8.01, p=0.0001) for infertility; A allele significantly overrepresented in cases (p<0.0001). The A allele appears to mark a subgroup of women whose high-normal or mildly elevated TSH reflects a fixed genetic setpoint, yet that setpoint is still high enough to impair the hormonal milieu of ovulation and implantation.

Separately, the Tromsø Study⁷⁷ Tromsø Study
Jorde et al., Thyroid 2014; 8,938 participants without thyroid disease; AA genotype 0.29 mIU/L higher TSH than GG; AA also associated with HR 1.14 for myocardial infarction (95% CI 1.00–1.29) extends the clinical picture beyond fertility: the same TSH-elevating mechanism that impairs reproduction may mildly elevate cardiovascular risk over a lifetime.

Practical Implications

The thyroid-fertility link is well-established in clinical endocrinology. Hypothyroidism — even subclinical — impairs ovulation through effects on sex hormone-binding globulin, prolactin secretion, and LH pulsatility. Implantation depends on adequate free T4 in the endometrium, and early placental development is exquisitely sensitive to maternal thyroid status. Current fertility guidelines (ESHRE, ATA) recommend TSH below 2.5 mIU/L before conception and in the first trimester.

For AA carriers, TSH levels between 2.5 and 4.0 mIU/L may represent a genetically elevated setpoint rather than early thyroid failure — but the biological consequences for egg quality, luteal phase, and implantation may be the same regardless of cause. The practical response is monitoring TSH before and during conception attempts, maintaining awareness that "normal range" TSH may not be the optimal target for this genotype, and bringing genotype data to any infertility or preconception evaluation.

Interactions

PDE8B rs6885099 and rs2046045: These two additional PDE8B intronic variants are in moderate linkage disequilibrium with rs4704397 and were examined in the Yang 2015 pregnancy cohort (PMID 25822812). All three independently associated with subclinical hypothyroidism risk in pregnant women, suggesting a haplotype-level effect on PDE8B expression. Individuals carrying the full high-TSH haplotype (A at rs4704397 + non-reference alleles at rs6885099 and rs2046045) show the strongest TSH elevation. This compound haplotype is a candidate for a consolidated monitoring action but has not yet been separately analyzed for fertility outcomes.

Thyroid autoimmunity (TPO antibodies): The TSH-raising effect of the A allele is genetically mediated and independent of thyroid peroxidase antibody (TPOAb) status. However, carriers who also have elevated TPOAb face a compounded risk: the baseline TSH is already shifted upward by PDE8B genetics, and autoimmune thyroiditis pushes it further. Women with AA genotype and positive TPOAb represent a high-priority group for preconception TSH optimization.

CD40 is a transmembrane receptor expressed on B cells, monocytes, dendritic cells, and other antigen-presenting cells. When its ligand CD40L (CD154) — displayed on activated T helper cells — binds CD40, it triggers a cascade that drives B-cell proliferation, antibody class switching, and germinal center formation. In plain terms, CD40 is the molecular handshake between T cells and B cells that tells the immune system to mount a full adaptive response. The variant rs4810485, located in intron 1 of the CD40 gene, acts as a rheostat: the G allele keeps the dial turned up, driving higher CD40 expression; the T allele turns it down.

The Mechanism

rs4810485 sits within a regulatory region of the first intron of CD40. Studies using electrophoretic mobility shift assays in synovial fibroblasts and immune cells have shown allele-specific binding at this exact position¹¹ allele-specific binding at this exact position
The G allele creates a stronger protein-binding signal than the T allele across multiple cell types including Jurkat (T cells), HT1080 (fibroblasts), and primary immune cells. Preliminary evidence from a Letter implicates RBPJ, the canonical effector of NOTCH signaling²² NOTCH signaling
NOTCH is a cell-cell communication pathway that controls differentiation and activation thresholds in immune cells, as a candidate binding factor. If confirmed, the G allele may create a binding site that recruits RBPJ more efficiently, elevating CD40 transcription.

The downstream consequence is measurable and consistent: compared with the GG genotype, individuals carrying GT or TT genotypes show significantly reduced CD40 mRNA and protein expression³³ significantly reduced CD40 mRNA and protein expression
Both basal and stimulated conditions tested in CD14+ monocytes and CD19+ B cells in peripheral blood B cells and monocytes. This is not a subtle effect — GG homozygotes have approximately 33% more CD40 on the surface of primary human B lymphocytes than TT homozygotes.

The Evidence

Rheumatoid Arthritis: The CD40 locus was identified as an RA susceptibility locus in a GWAS meta-analysis of 3,393 cases and 12,462 controls⁴⁴ GWAS meta-analysis of 3,393 cases and 12,462 controls
Analysis combined multiple genome-wide studies and applied replication in 3,929 ACPA-positive RA cases and 5,807 controls (OR 0.87, p=8.2×10⁻⁹ for the T allele — the T allele is protective). A large UK replication study⁵⁵ large UK replication study
3,962 UK RA patients versus 3,531 healthy controls recruited across five centres confirmed the association (OR 0.86 per T allele, p=7.8×10⁻⁸ after meta-analysis).

Beyond disease onset, rs4810485 influences disease course: TT homozygotes show higher rates of joint destruction in ACPA-positive RA⁶⁶ higher rates of joint destruction in ACPA-positive RA
Primary cohort of 563 RA patients; ACPA-positive subset used; replicated in 393 ACPA-positive patients in NARAC cohort (p=0.003, replicated in an independent cohort at p=0.021), making it one of the first non-HLA genetic severity factors replicated in RA.

Systemic Lupus Erythematosus: In a combined Greek and Turkish cohort, the T allele was significantly under-represented in SLE patients⁷⁷ the T allele was significantly under-represented in SLE patients
509 SLE patients and 825 healthy controls across two cohorts (combined OR 0.63, 95% CI 0.53–0.74, p=2×10⁻⁸), with the same allele-specific expression pattern found in cases and controls alike.

Crohn's Disease and Multiple Sclerosis: rs4810485 is in tight linkage disequilibrium (r²=0.95) with rs1883832, a CD40 promoter variant. Studies of rs1883832 showed a novel association with Crohn's disease⁸⁸ novel association with Crohn's disease
Spanish cohort genotyped for rs1883832; CD patients vs population controls (OR 1.19, p=0.002) and replication in multiple sclerosis susceptibility (OR 1.12, p=0.025). Notably, the susceptibility allele for RA/SLE appears protective in MS — the CD40 locus shows disease-specific directional effects, implying that the optimal level of CD40 signaling differs across distinct autoimmune processes.

Graves' Disease and Therapeutic Relevance: In a precision medicine study of Graves' disease patients treated with iscalimab (an anti-CD40 monoclonal antibody), treatment responders were enriched for the G-allele haplotype⁹⁹ treatment responders were enriched for the G-allele haplotype
13 Graves disease patients treated with iscalimab; genotyped for rs4810485 and flanking CD40 SNPs while non-responders predominantly carried T-allele haplotypes (p=0.0008). This provides proof-of-concept that rs4810485 genotyping may one day guide selection of anti-CD40 pathway therapies.

Practical Actions

For GG carriers, the elevated CD40 expression on B cells creates the foundation for heightened autoimmune B-cell activity. The key implication is not a single actionable nutrient or supplement, but rather a set of monitoring priorities: early detection of autoimmune conditions, awareness of how anti-CD40L biologics may be particularly relevant if they are ever prescribed, and avoidance of exposures known to trigger autoimmunity in genetically predisposed individuals.

For TT homozygotes, the reduced CD40 expression appears protective against most autoimmune diseases studied — but the picture is complex. In multiple sclerosis, the low-CD40 T allele may increase susceptibility, and in RA patients who carry the TT genotype, evidence suggests faster joint destruction despite lower disease onset risk. TT carriers should still be monitored for RA if symptoms develop, as the TT genotype does not fully eliminate risk.

Interactions

CD40 rs4810485 acts within the broader adaptive immune network. The most relevant co-regulatory variants in the database are rs2476601 (PTPN22 R620W, affecting T-cell signaling threshold) and rs3087243 (CTLA4 CT60, the T-cell checkpoint). In individuals who carry risk alleles at multiple nodes of T-cell/B-cell co-stimulation, the combined dysregulation may be substantially greater than any single variant predicts. Functional studies specifically on the CD40–PTPN22 and CD40–CTLA4 combined effects are limited, but these variants all converge on the same germinal center reaction pathway. Future compound action entries in this category will capture these combined interactions when supported by published evidence.

Hydrogen sulfide (H₂S) is not just an industrial gas — it is one of the body's own signaling molecules, produced enzymatically in vascular tissue and the placenta to regulate blood flow, suppress inflammation, and protect against hypoxic injury. The enzyme responsible in the cardiovascular system is cystathionine gamma-lyase (CTH, also called CSE)¹¹ cystathionine gamma-lyase (CTH, also called CSE)
encoded by CTH on chromosome 1p31; converts cystathionine to cysteine with H₂S as a byproduct of cysteine catabolism. During pregnancy, CTH-derived H₂S becomes critically important: it dilates placental arteries, counteracts the anti-angiogenic factors that can cause preeclampsia, and promotes the deep placental invasion required for normal fetal growth.

rs482843 is a common intronic variant in CTH (GRCh38 chr1:70,406,697, A>G). Unlike the missense variant rs1021737 (Ser403Ile), rs482843 does not alter the protein sequence. Its functional consequence is regulatory — the intronic position (c.-120+401A>G per Ensembl annotation) likely affects splicing efficiency, transcription factor binding within an intronic regulatory element, or mRNA processing, with net effects on CTH expression levels in placental tissue. The G allele — specifically the GG genotype — carries significantly elevated preeclampsia risk in Caucasian women, while rs1021737 (the coding variant in the same gene) shows no preeclampsia association in the same population.

The Mechanism

Preeclampsia is characterized by inadequate placental vascularization, release of anti-angiogenic factors (sFlt-1 and soluble endoglin), and systemic maternal hypertension after 20 weeks' gestation. The H₂S/CTH system functions as a protective brake²² protective brake
described by Ahmed & Ramma 2015 as an "accelerator-brake" model where loss of endogenous H₂S production removes the protective counter-signal against pathological vascular stress against this process. H₂S generated by CTH in placental trophoblasts and vascular smooth muscle suppresses sFlt-1 and soluble endoglin release, promotes placental growth factor (PlGF) signaling, and maintains endothelial nitric oxide synthase (eNOS) activity — all of which are deficient in preeclampsia.

Experimental work by Ahmed et al. 2017³³ Experimental work by Ahmed et al. 2017
Ahmed A, Rezai H, Broadway-Stringer S. Evidence-Based Revised View of the Pathophysiology of Preeclampsia. Adv Exp Med Biol. 2017. showed that augmenting the H₂S/Cth pathway in mouse preeclampsia models restored placental vasculature and improved fetal growth. If rs482843's G allele reduces CTH expression in placental tissue — even modestly — the protective H₂S signal may be insufficient to prevent the cascade that leads to preeclampsia.

Importantly, this is a placenta-specific phenotype. The same variant shows no significant association with essential hypertension in non-pregnant adults (Li et al. 2008; n=993 Han Chinese adults), suggesting the G allele's effect is conditional on the unique vascular demands of pregnancy, where H₂S production must scale dramatically to accommodate placental blood flow.

The Evidence

The primary association comes from Mrozikiewicz et al. 2015⁴⁴ Mrozikiewicz et al. 2015
The importance of rs1021737 and rs482843 polymorphisms of cystathionine gamma-lyase in the etiology of preeclampsia in the Caucasian population. Ginekol Pol. 2015;86(2):119–25. a case-control study of 60 women with preeclampsia and 120 healthy pregnant controls from a Caucasian Polish population. The GG genotype of rs482843 was significantly more prevalent in preeclampsia cases than controls (p<0.000001), with the G allele itself also reaching genome-wide significance thresholds (p<0.000001). Critically, the companion coding variant rs1021737 showed no significant association with preeclampsia in the same cohort — indicating that rs482843 is the functionally relevant CTH variant for pregnancy-specific vascular dysfunction, while rs1021737 operates through a distinct mechanism relevant to cardiovascular and homocysteine metabolism.

The finding has not yet been replicated in independent large cohorts, and the study size (n=180 total) limits precision. The biological plausibility is strong given the mechanistic data on H₂S in placental biology, but independent replication in diverse populations is needed before this reaches "strong" evidence status.

Practical Actions

For women with the GG genotype who are pregnant or planning pregnancy, the actionable focus is on supporting CTH enzyme output through its cofactor requirements and dietary precursors. CTH is a pyridoxal-5-phosphate (PLP)-dependent enzyme⁵⁵ pyridoxal-5-phosphate (PLP)-dependent enzyme
PLP is the bioactive form of vitamin B6, required for all transsulfuration enzymes including CTH — ensuring optimal B6 status is a direct biochemical support for CTH activity. Providing abundant cysteine precursors (eggs, garlic, onions, cruciferous vegetables) and early prenatal monitoring for preeclampsia signs (blood pressure, proteinuria, placental growth factor levels) are the practical priorities.

Women with the AG genotype have an intermediate picture. The allele-dose effect is consistent with codominant inheritance, and AG carriers warrant prenatal vigilance without the same urgency as GG.

Interactions

rs482843 and rs1021737 are two independent CTH variants with distinct phenotypic profiles — rs482843 is relevant to preeclampsia risk, rs1021737 to homocysteine and cardiovascular disease. A woman carrying GG at rs482843 and TT at rs1021737 would have both H₂S insufficiency during pregnancy and impaired transsulfuration at baseline, creating a compounded vulnerability. Elevated homocysteine from rs1021737 TT is itself a known risk factor for preeclampsia, adding a second mechanistic pathway.

The H₂S system also interacts with eNOS (NOS3): H₂S produced by CTH enhances endothelial nitric oxide availability. Women carrying NOS3 variants with reduced eNOS activity alongside CTH rs482843 GG may face a dual vasodilatory deficit in the placenta.

The rs524952 variant sits in a regulatory region near the GJD2 gene on chromosome 15q14, one of the first and most consistently replicated genetic associations with myopia¹¹ one of the first and most consistently replicated genetic associations with myopia
discovered in genome-wide association studies since 2010. GJD2 encodes connexin 36 (Cx36), a gap junction protein that forms channels between neuronal cells in the retina, enabling the exchange of ions and small molecules critical for visual signal transmission²² retina, enabling the exchange of ions and small molecules critical for visual signal transmission
Gap junctions are essential for coordinating electrical activity in retinal circuits. While rs524952 itself lies outside the coding region of GJD2, it appears to influence gene expression levels, affecting how efficiently retinal neurons communicate during the critical period of eye development.

The Mechanism

Gap junctions formed by connexin 36 are particularly abundant in the inner retina, connecting amacrine cells, bipolar cells, and ganglion cells³³ inner retina, connecting amacrine cells, bipolar cells, and ganglion cells
These connexins enable synchronized electrical activity across retinal circuits. Animal studies have demonstrated that disruption of connexin 36 function leads to defects in the ON pathway of rod signaling, and mice with defective ON pathways develop myopia⁴⁴ defects in the ON pathway of rod signaling, and mice with defective ON pathways develop myopia
The ON pathway processes light increments and is critical for emmetropization—the process by which the eye grows to the correct length. The rs524952 A allele appears to alter GJD2 expression, potentially disrupting this finely tuned signaling system. In guinea pig myopia models, researchers found 31-38% decreased GJD2 mRNA and connexin 36 protein levels in myopic eyes compared to controls⁵⁵ 31-38% decreased GJD2 mRNA and connexin 36 protein levels in myopic eyes compared to controls
This suggests reduced gap junction function may permit excessive axial elongation.

The Evidence

The association between rs524952 and myopia has been replicated across multiple large studies and diverse populations. A 2013 meta-analysis of 45,758 individuals of European and Asian ancestry⁶⁶ 2013 meta-analysis of 45,758 individuals of European and Asian ancestry
Verhoeven et al., Nature Genetics, 2013 found the A allele associated with more myopic refractive error (β = -0.158 diopters, P = 1.44 × 10⁻¹⁵). In Japanese populations, the alternate allele showed an odds ratio of 1.32 for high myopia in the Japanese cohort⁷⁷ the alternate allele showed an odds ratio of 1.32 for high myopia in the Japanese cohort
Hayashi et al., Investigative Ophthalmology & Visual Science, 2011. Importantly, this variant shows strong gene-environment interaction with education: in individuals with university education, each A allele conferred -0.31 diopters of myopia, while in those with lower education the effect was only -0.08 diopters⁸⁸ strong gene-environment interaction with education: in individuals with university education, each A allele conferred -0.31 diopters of myopia, while in those with lower education the effect was only -0.08 diopters
Fan et al., Human Molecular Genetics, 2014, suggesting that environmental factors like near work amplify the genetic risk.

Children carrying A alleles show progressive myopia development starting as early as age 6, with a clear dose-response pattern: those with two A alleles have the longest axial length, followed by one A allele, with TT individuals having the shortest eyes⁹⁹ progressive myopia development starting as early as age 6, with a clear dose-response pattern: those with two A alleles have the longest axial length, followed by one A allele, with TT individuals having the shortest eyes
Haarman et al., Investigative Ophthalmology & Visual Science, 2021. The GJD2 risk genotype appears to drive myopia primarily through enlarged vitreous depth, possibly compensated by subtle thinning of the cornea and lens¹⁰¹⁰ enlarged vitreous depth, possibly compensated by subtle thinning of the cornea and lens
Rotterdam Study phenotype analysis. A study of 1,043 Hong Kong children found rs524952 A allele carriers had significantly faster myopia progression over 3 years, with polygenic risk scores including this variant showing 2.26-fold increased risk of fast progression¹¹¹¹ study of 1,043 Hong Kong children found rs524952 A allele carriers had significantly faster myopia progression over 3 years, with polygenic risk scores including this variant showing 2.26-fold increased risk of fast progression
Chen et al., British Journal of Ophthalmology, 2021.

Practical Implications

For individuals carrying one or two A alleles, the primary concern is increased susceptibility to myopia, particularly when combined with high educational demands or intensive near work. Myopia itself is more than a simple inconvenience requiring glasses—it increases lifetime risk of sight-threatening complications including myopic macular degeneration, retinal detachment, glaucoma, and cataracts¹²¹² sight-threatening complications including myopic macular degeneration, retinal detachment, glaucoma, and cataracts
particularly concerning in high myopia (worse than -6 diopters). The gene-environment interaction suggests that lifestyle modifications during childhood may be particularly effective for genetic risk carriers.

For children with AA or AT genotypes, consider more frequent eye exams starting around age 6 to catch myopia early when interventions are most effective. Emerging evidence suggests that outdoor time may protect against myopia progression¹³¹³ outdoor time may protect against myopia progression
The protective effect may work through dopamine signaling pathways that also interact with gap junction function. Aim for at least 2 hours of outdoor time daily, especially during school-age years when the eye is actively growing. Myopia control interventions like specialized contact lenses (MiSight) or low-dose atropine eye drops can slow progression by approximately 59% over 3 years¹⁴¹⁴ specialized contact lenses (MiSight) or low-dose atropine eye drops can slow progression by approximately 59% over 3 years
Chamberlain et al., Optometry and Vision Science, 2019.

Interactions

rs524952 interacts with other myopia-associated variants to compound risk. Studies have examined interactions with rs7744813 (KCNQ5), rs13382811 (ZFHX1B), and rs634990 (another GJD2 variant in high linkage disequilibrium with rs524952). When rs524952 is combined with KCNQ5 and ZFHX1B variants, the combined polygenic risk score significantly predicts both myopia onset and progression rate in children, suggesting these variants work through partially overlapping pathways affecting eye growth regulation. Multiple myopia loci including GJD2 show stronger associations in highly educated individuals, possibly because extended near work creates an environment where reduced retinal signaling capacity becomes limiting.

Iron absorption is not a passive process — it is under continuous hormonal control by hepcidin¹¹ hepcidin
A 25-amino-acid peptide hormone produced by the liver that blocks ferroportin, the only known mammalian iron export channel, on gut and macrophage cell surfaces. When hepcidin rises, iron absorption falls, and TMPRSS6 is the gene whose job it is to keep that hormone in check. TMPRSS6 encodes matriptase-2²² matriptase-2
A type II transmembrane serine protease expressed in the liver that cleaves hemojuvelin from the hepatocyte surface, disabling the BMP/SMAD signaling cascade that drives hepcidin transcription. Loss of matriptase-2 activity leads to chronically elevated hepcidin and iron-refractory anemia, the molecular brake on hepcidin production. While the coding-change variant rs855791 (Ala736Val) alters the catalytic efficiency of this enzyme directly, the TMPRSS6 locus harbors additional intronic variants that collectively refine the iron-regulatory output of the gene at the population level. rs5756504 is one of these.

Located at position c.1556-198 within intron 13 of TMPRSS6 — 122 nucleotides downstream of the nearby intronic variant rs5756506 — rs5756504 carries no amino acid change and no direct protein consequence. Instead, it falls within a region of the TMPRSS6 pre-mRNA that influences downstream splicing or transcriptional regulation. The C allele, which is the GRCh38 reference and the population-major allele in European and South Asian populations, is associated with lower hemoglobin. The T allele, more common in African populations, is associated with higher hemoglobin and better erythrocyte parameters.

The Mechanism

Like its neighbor rs5756506, rs5756504 is an intronic variant with no direct protein consequence. Intronic variants in this position can alter TMPRSS6 expression or processing through several routes: modification of branch point or polypyrimidine tract sequences affecting spliceosome recruitment, disruption of intronic regulatory elements that influence transcription factor occupancy, or tag-SNP effects reflecting LD with a causal nearby variant. The net effect — reflected in population-level hemoglobin differences — is consistent with modulation of the TMPRSS6/hepcidin axis: higher T allele dosage correlates with more effective hepcidin suppression and therefore greater iron absorption and higher hemoglobin.

The variant is located approximately 122 nucleotides from rs5756506 within the same intronic region. Whether these two variants act independently or tag the same causal signal has not been formally resolved in published fine-mapping studies, though their coexistence in multiple independent TMPRSS6 iron-status studies suggests each contributes information.

The Evidence

The primary association evidence comes from a large GWAS of hematological traits³³ large GWAS of hematological traits
Kamatani Y et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet, 2010 in 14,402 Japanese individuals, which identified rs5756504-T as associated with higher hemoglobin at genome-wide significance (P = 2 × 10⁻¹⁰, effect size approximately +0.076 g/dL per T allele). This signal is independent of the lead TMPRSS6 coding variant rs855791 based on the study's locus-wide analysis.

A subsequent replication study⁴⁴ replication study
Seiki T et al. Association of genetic polymorphisms with erythrocyte traits: Verification of SNPs reported in a previous GWAS in a Japanese population. Gene, 2018 in 4,971 Japanese participants from the Japan Multi-Institutional Collaborative Cohort Study confirmed the rs5756504 association with erythrocyte traits, including hemoglobin and related red cell indices. A systematic review⁵⁵ systematic review
Timmer T et al. Associations between single nucleotide polymorphisms and erythrocyte parameters in humans: a systematic literature review. Mutat Res Rev Mutat Res, 2019 subsequently listed rs5756504 among fourteen SNPs consistently associated with mean corpuscular hemoglobin across multiple cohorts.

The evidence base is moderate — two independent cohort populations with replicated association, a biologically coherent mechanism via the TMPRSS6/hepcidin pathway, and a signal that appears distinct from the established coding variant rs855791. The effect size (~0.076 g/dL per allele) is comparable to that of other common TMPRSS6 intronic variants.

Practical Implications

For individuals homozygous for the C allele (CC), the functional consequence mirrors that of other low-hemoglobin TMPRSS6 genotypes: modestly reduced iron absorption efficiency through the hepcidin pathway. The margin of iron sufficiency is thinner. During periods of elevated iron demand — menstruation, pregnancy, endurance training, or reliance on plant-based diets with lower non-heme iron bioavailability — CC individuals may deplete iron stores more readily than T allele carriers.

For heterozygotes (CT), the effect is intermediate. For TT individuals, the genotype is associated with the highest hemoglobin in this locus and confers no additional monitoring burden beyond standard practice.

Interactions

rs5756504 sits within the same TMPRSS6 locus as the coding variant rs855791 (Ala736Val) and the adjacent intronic variant rs5756506. These three variants collectively shape the iron-regulatory output of the matriptase-2 axis. Whether rs5756504 and rs5756506 are in linkage disequilibrium with each other or tag independent functional signals is not fully established in published literature.

The rs855791 coding variant remains the primary determinant of TMPRSS6-mediated iron status, with each A allele reducing hemoglobin by approximately 0.13 g/dL — roughly twice the per-allele effect of rs5756504. Carrying the CC genotype at rs5756504 alongside the AA genotype at rs855791 represents additive pressure on hepcidin regulation, with both variants independently raising hepcidin and reducing iron absorption. In individuals who also carry HFE hemochromatosis variants (rs1800562 C282Y, rs1799945 H63D), the cumulative hepcidin-raising effect of TMPRSS6 variants may partially offset the pathological iron loading driven by HFE dysfunction.